Millions of cancer patients promised faster diagnosis with help of new tech tool
The tool, called Cancer 360, brings cancer patients' data into one central system, so clinicians can prioritise those most in need and see patients quicker, the DHSC said.
It moves existing analogue systems to a digital one, so staff will not have to gather important information about each cancer patient from different spreadsheets, emails, and records.
Dr Vin Diwakar, NHS national clinical transformation director, said: 'Every cancer patient deserves swift, effective care, and our new Cancer 360 solution harnesses data to ensure exactly that. By giving clinicians a comprehensive view of patient pathways, we can identify and address delays immediately.
'The NHS federated data platform (FDP) is already showing its value in transforming cancer care, helping our hard-working staff deliver better outcomes while reducing administrative burden. As Cancer 360 expands to more hospitals nationwide, I'm confident we'll see meaningful improvements in both treatment times and patient experience.'
It is understood that trusts will not have to use the tool, but those not meeting the cancer standard – including that 85% of cancer patients should have started their treatment within 62 days of being referred – may be asked to consider how Cancer 360 could help them meet targets.
As well as helping patients get a faster diagnosis, the DHSC said Cancer 360 will also help cut treatment delays and thus boost survival rates.
The technology has been piloted at Royal United Hospital Bath, and Chelsea and Westminster Hospital.
It helped Chelsea and Westminster Hospital meet the faster diagnosis standard, whereby 75% of patients should receive a diagnosis or ruling out of cancer within 28 days of referral.
Suraiya Abdi, consultant obstetrician and gynaecologist at Chelsea and Westminster Foundation Trust, said: 'The implementation of Cancer 360 has enabled my team to monitor and safely carry our patients through their cancer pathway.
'The tool enables us to have in depth conversations at our weekly meetings regarding a patient's next step as well as allowing us to escalate queries directly to other teams for faster turnaround.
'The tool has reduced the amount of admin time spent by our cancer team therefore enabling them to focus on the patient journey. I have witnessed an improvement in performance, team spirit and most importantly patient experience.'
Technology Secretary Peter Kyle said: 'I've seen first-hand the stress and heartbreak that cancer causes in my own family.
'Dependent on archaic pen-and-paper systems, life-saving diagnostics appointments hung on whether a post-it note lost its stick, or a piece of paper went missing. That put lives at risk, and with the technology we have today, there's no reason for any part of our healthcare service to run in such a way.
'Simply by keeping accurate records, the technology we are putting to work today will cut waiting times and save lives, delivering on our plan for change. That way, people can once again trust that their local hospital has the tools it needs to focus on what matters – treating their loved ones and keeping families together for longer.'
Health Secretary Wes Streeting said the Government is investing £26 billion in the health service, adding: 'It's a long road but we're already getting our NHS back on its feet, giving patients over three million more appointments, hiring 1,500 new GPs and starting the roll-out of new tech that will save lives.'
The DHSC said Cancer 360, to be rolled out soon, will benefit millions of patients in the next five to 10 years.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
25 minutes ago
- Daily Record
Man struggled to eat sandwich at work and only has six months to live
Des Longstaff was diagnosed with stage four cancer that spread from his windpipe to his liver. A tragic dad who was diagnosed with stage four cancer after struggling to eat a sandwich at work has been told he'll be dead in the next six months. Des Longstaff, 40, from Blackpool, was being treated for an aggressive stage four oesophageal adenocarcinoma, which spread from his windpipe to his liver. But, sadly treatment has now stopped and the courageous father is now sharing his story one final time to raise awareness about the cruel disease. His story rocked the nation earlier this year, after he revealed to us the simple act of eating a sandwich led to his devastating diagnosis, reports the Mirror. In a devastating health update, he explained: "I have about six months to live. I was told yesterday. I have had a tough life and I genuinely would do anything for anyone. I am still trying to help people out now. I don't feel poorly. But I won't be having any more treatments. "I will die with dignity. I put up a good fight, I never lost a fight yet but this time is different. I'm not scared of dying, I just don't want to leave the people that need me still. "I am ready for death now. I hope that people can still donate to my son's GoFundMe so he can get his life together without this daddy who loves him so very much. I fought for him until the day I died I suppose. "I'm sorry I let everyone down but thank you so much for the support. I hope you all remember me this way." Oesophageal cancer affects the oesophagus, the tube that carries food from people's throat to their stomach, and according to the NHS, it mainly impacts people in their 60s and 70s, and is more common in men. Symptoms of the disease can include difficulty swallowing, indigestion, loss of appetite and weight, pain in your upper tummy, chest or back or bringing up food soon after eating. For Des, who is a landscape gardener, he first realised something wasn't right with his body while at work one day. Speaking to Reach PLC earlier this year, he said: "I am a landscaper by trade and I was doing a job for one of my friends and his partner had made me a bacon and sausage sandwich. When I was eating it – I hadn't put any sauce on or anything – it sort of got lodged in my oesophagus and I had a good pint of water but it still wouldn't budge. "It was to the point where you're thinking you're choking. I thought to myself, 'Am I not chewing it properly?" Des went to a doctor and an endoscopy was recommended – but he threw up blood and noticed more blood in his stool before this happened. After going to the hospital, a 35cm tumour was discovered in his lower oesophagus on Christmas Eve. It was hoped that keyhole surgery would remove the tumour but another scan revealed it has spread to his liver. Cancer Research UK states that advanced stage four esophageal adenocarcinoma, which means the cancer has spread from the food pipe to other areas of the body, usually cannot be cured.. Des had been fundraising to go to Germany for alternative treatments so he could see his little boy, five, grow up, but he has been told he is now too poorly. He emphasised the brutality of his previous treatment, saying immunotherapy and chemotherapy made him feel 'more sick than the cancer'. Des also said he has suffered extreme stress in his personal life away from his health battle which he believes progressed his condition. Giving a brief summary, he simply said: 'I've been through hell.' And in a poignant recent post on social media, he wrote: "The king and the little prince. He's going to be the king. He will do it better than I. My spirit will live in him always. My love of life he is."
Scotsman
an hour ago
- Scotsman
The things to consider before getting cosmetic surgery abroad
The government is bringing in new regulations in the UK as part of a cosmetic surgery crackdown 💉 Sign up to our daily newsletter – Regular news stories and round-ups from around Scotland direct to your inbox Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... More people are turning to social media to research cosmetic surgery abroad. People are travelling for procedures like hair transplants and dental work. However, when something goes wrong, the NHS is left with the cost. More people than ever are turning to social media for information about cosmetic surgeries abroad, travelling for procedures like hair transplants or dental work. However, when things go wrong, the NHS is often left to pick up the cost. To help ensure patients have trustworthy information, the government and TikTok have partnered with medical influencers to create content showing the risks and advising on how to make trips as safe as possible. Advertisement Hide Ad Advertisement Hide Ad It comes after the government announced new regulations on cosmetic procedures in the UK. The highest-risk procedures, such as non-surgical Brazilian butt lifts, can only be carried out by qualified, specialised healthcare professionals, registered with the Care Quality Commission. Whilst measures will also include a licensing scheme for lower-risk procedures such as Botox and fillers, alongside minimum age restrictions. The government is also bringing in new regulations for cosmetic procedures in the UK. | Pexels, cottonbro studio Health Minister Karin Smyth said: 'Too many people are being left with life-altering injuries after going abroad for medical procedures, without access to proper advice or safeguards, often drawn in by deals too good to be true and promoted by influencers - some of whom have never been to the practice in question. 'By partnering with TikTok, we're helping people make safer, more informed choices before they go under the knife - wherever that may be. Advertisement Hide Ad Advertisement Hide Ad 'Through our Plan for Change, we're determined to protect patients, ease pressure on the NHS and make sure taxpayers are not left paying the price when things go wrong.' What should you consider before getting cosmetic surgery abroad? There are many things to consider before travelling abroad for cosmetic procedures or surgery. The new advice is calling on potential patients to talk with a UK doctor first and research the clinic they plan to travel to. Advertisement Hide Ad Advertisement Hide Ad Check if the clinic is registered and the surgeon's credentials. The NHS advises that before deciding on a clinic, you should find out how surgeons and clinics are regulated in your chosen country and how standards are enforced. Before the procedure, you should have two consultations with the surgeon. This gives you a two-week cooling-off period, which is normally two weeks in the UK. What should you ask your surgeon? In these consultations, the surgeon should explain what the procedure involves, the limitations, alternatives, and any risks or complications. They should also be able to show you before-and-after pictures of their work. Plan for any risks or complications, ask what insurance the clinic or surgeon has and if it will cover you, find out what your travel insurance covers and how you'll get home in the case of an emergency, and most importantly, how much this will cost. Advertisement Hide Ad Advertisement Hide Ad How to check if a person is qualified? Each country will have its registration system and accreditation body. In England, all hospitals and clinics that provide cosmetic surgery must be registered with the Care Quality Commission (CQC).
Telegraph
an hour ago
- Telegraph
NHS to hand out more fat jabs after private clinics raise prices
The NHS will prescribe the weight-loss jab Mounjaro to more people in response to a dramatic price increase for private patients, The Telegraph can reveal. GPs are being braced for a surge in demand for the 'King Kong' of weight-loss jabs after Eli Lilly, the US pharmaceutical firm, said it would be more than doubling its prices from Sept 1. Health officials have written to family doctors about an expected increase in demand from patients who had been accessing the drug privately, but will now turn to the NHS. The Government is also looking to intervene in the dramatic price rise, it is understood, amid fears that hundreds of thousands of patients currently benefiting from losing weight on the jabs could be forced to stop taking them. Eli Lilly said it was increasing the cost of Mounjaro – also known as tirzepatide – in the UK to bring it in line with 'other developed nations'. In July, Donald Trump demanded that drug manufacturers lower their prices for American patients and stop other countries 'freeloading' off US firms. The US president previously complained that a friend had the 'fat drug' in London for a fraction of its US price despite being 'the same box made in the same plant by the same company'. Eli Lilly is increasing the wholesale price UK retailers will pay for a middle-sized 5mg dose from £92 to £180, and for the maximum dose, 15mg, from £122 to £330. These costs are likely to be passed on to private patients, of which there are almost one million taking Mounjaro, most of whom will now face the choice of paying the increased rates or stopping the drug. But the NHS has said it will continue prescriptions for patients who had been accessing the drugs privately if they meet certain criteria. The health service has a commercial deal in place to roll out the jab at a cheaper price. The cost of a prescription to patients is £9.90. A letter from NHS officials to GPs seen by The Telegraph said the NHS could continue treatment 'for people that have previously accessed tirzepatide through a private provider' if they meet eligibility criteria when assessed by a weight management service. Under current guidance, patients must have a body mass index of 40 or more 'in addition to four or more qualifying comorbidities', such as diabetes and high blood pressure, as part of a phased rollout. From next April, people with a BMI of 35 or more will also be able to get the jab on the NHS, with plans to eventually roll it out to more than three million. People accessing the anti-obesity injections privately are supposed to have a BMI of more than 30, but some people have been 'cheating the system' in order to access it, according to Wes Streeting, the Health Secretary. It is not known how many people will be eligible to move over to an NHS prescription from a private one. There were 32,000 patients waiting for an appointment at a weight management service in the community as of the end of June. While the majority of patients are being seen within 18 weeks, more than 2,000 have been waiting for more than a year. NHS officials also said GPs should tell patients asking for weight-loss jabs if they are not currently eligible. This includes those who may have started treatment with a BMI of more than 40 but is now less. 'We recognise this may be disappointing for people,' the update said, adding that doctors 'could provide reassurance to the person that stopping tirzepatide, that is being taken for its licensed weight loss indication, is not known to cause withdrawal symptoms, but that they should continue, where appropriate, a reduced-calorie diet and increased physical activity if they want to reduce the risk of weight regain'. It said anyone with questions about stopping the drugs should be directed back to their private provider. More people could also turn to the other weight-loss jab available in the UK, rival brand Wegovy, made by Danish firm Novo Nordisk. A spokesman for the company, which also makes Ozempic, said they had 'no plans of changing our offering in the UK'. 'Our focus is on supporting patients, and we are committed to ensuring that our medicines are not only innovative but also accessible and affordable for those who need them most,' they said. 'Our mission is to help create a healthier world by addressing some of the most pressing threats to public health – including obesity, diabetes and cardiovascular disease.' A Department of Health spokesman said: 'This government is committed to ensuring that more people have access to these revolutionary drugs when needed, and crucially that they are able to so do in a safe and controlled way. 'Pricing in the private market is a matter for Eli Lilly and for private providers of weight loss and diabetes services. Eli Lilly are working with providers to maintain patient access. 'NHS commissioning of tirzepatide, based on clinical priority, is unaffected by the change in list price.'
